Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
This study evaluates the efficacy of Long-acting Somastostatin analogs as treatment for type I gastric neuroendocrine tumors.
Gastric NET
DRUG: Octreotide
Recurrence rate, 1 year
Change in clinical symptoms, Measured by a questionnaire, including whether the patient presents with dyspepsia, abdominal pain, cramps, bloating, nausea, vomiting, lack of appetite, facial flushing., 6 months to 1 year|Concentration of serum Gastrin, Concentration of serum Gastrin after 12 hours of fasting, 6 months to 1 year|Enterochromaffin-like cell (ECL) status, Normal Hyperplasia: ECL cell proliferation with a diameter \<150 μm, distinguished in: normal pattern/simple hyperplasia, linear, micronodular and adenomatoid hyperplasia.

Dysplasia: ECL cell proliferation \>150 but \<500 μm. Type I gastric carcinoid: ECL proliferation \>500 μm., 6 months to 1 year|Presence of side-effects of Octreotide, Measured by a questionnaire for patients and clinician's report. Including: hypersensitivity, endocrine disorders (abnormal thyroid functions), metabolism and nutrition disorders (abnormal blood glucose), headache, bradycardia or tachycardia, dyspnea, gastrointestinal disorders (diarrhea, abdominal pain, nausea, constipation, flatulence), hepatobiliary disorders, skin disorders, injection site reaction., 6 months to 1 year
This study evaluates the efficacy of Long-acting Somastostatin analogs as treatment for type I gastric neuroendocrine tumors.